Bristol-Myers Squibb Company (BMY)
NYSE · Healthcare · Drug Manufacturers - General
Profile
Bristol-Myers Squibb Company
- Exchange
- NYSE
- Ticker
- BMY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- US
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Key facts
Bristol-Myers Squibb Company: key facts
- Bristol-Myers Squibb Company (NYSE: BMY) is a Drug Manufacturers - General company in the Healthcare sector.
- In fiscal 2025, Bristol-Myers Squibb Company reported revenue of $48.2B and net income of $7.1B.
- Revenue grew 1.0% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 4 of the last 5 fiscal years.
- Over the last twelve months, revenue was $50.0B and net income was $9.2B.
MonkScore
Bristol-Myers Squibb Company's MonkScore
MonkScore
MonkScore range: 80–90
as of October 2026
Sector rank: 137 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth60–70
- Profitability70–80
- Quality80–90
- Market Conviction60–70
- Safety40–50
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Bristol-Myers Squibb Company's annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $50.0B | $48.2B | $48.3B | $45.0B | $46.2B | $46.4B |
| Gross profit | $34.6B | $34.3B | $34.3B | $34.3B | $36.0B | $36.4B |
| Operating income | $13.0B | $13.7B | $5.9B | $8.2B | $9.1B | $8.5B |
| Net income | $9.2B | $7.1B | -$8.9B | $8.0B | $6.3B | $7.0B |
| Operating cash flow | $10.7B | $14.2B | $15.2B | $13.9B | $13.1B | $16.2B |
| Capital expenditure | -$1.4B | -$1.3B | -$1.2B | -$1.2B | -$1.1B | -$973.0M |
| Free cash flow | $9.3B | $12.8B | $13.9B | $12.7B | $11.9B | $15.2B |
| Total debt | $42.9B | $47.1B | $51.2B | $41.5B | $40.7B | $45.6B |
| Cash | $9.6B | $10.2B | $10.3B | $11.5B | $9.1B | $14.0B |
Revenue growth a year
- 1-year
- -0.2%
- 3-year
- 1.4%
- 4-year
- 1.0%
Compound growth between fiscal years.
Peers
Similar companies
- Amgen Inc.NASDAQ:AMGNMonkScore range: 90–100
- AbbVie Inc.NYSE:ABBVMonkScore range: 90–100
- Gilead Sciences, Inc.NASDAQ:GILDMonkScore range: 90–100
- Eli Lilly and CompanyNYSE:LLYMonkScore range: 90–100
Compare
Compare with
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
Free tools for Bristol-Myers Squibb Company: Dividend calculator
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.